CHADDS FORD, Pa., April 8 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals will announce its first quarter financial results on April 29, 2009 and will host a conference call and webcast at 10:30 a.m. ET that day to discuss these results.
David P. Holveck, president and chief executive officer, Nancy J. Wysenski, chief operating officer, Ivan Gergel, M.D., executive vice president of research and development and Blaine Davis, vice president, corporate affairs will host the call.
Investors and other interested parties may call 866-383-7998 (domestic) or 617-597-5329 (international) and enter passcode 54725288. Please dial in 10 minutes prior to the scheduled start time.
A replay of the call will be available from April 29 at 1:30 p.m. ET until 12:00 a.m. ET on May 6 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and enter passcode 95260431.
A simultaneous webcast of the call may be accessed by visiting http://www.endo.com/. In addition, a replay of the webcast will be available until 12:00 a.m. ET on May 6. The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.
About Endo
Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment; SANCTURA(R) and its XR version for treatment of overactive bladder; VANTAS(R) for the palliative treatment of advanced prostate cancer; and SUPPRELIN(R) for the treatment of early onset puberty in children, or CPP. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at http://www.endo.com/.
Endo Pharmaceuticals
CONTACT: Blaine Davis, +1-610-459-7158
Web Site: http://www.endo.com/
